The UCI DMA &Protein MicroArray Facility was initially established in 1999 as a Comprehensive Cancer Center Shared Resource Core Facility, directed at assisting both North and South Campus investigators performing microarray expression analysis. About 200 investigators inside and outside the South Campus have been provided services in the last five year period. We primarily utilize the Affymetrix GeneChip array system to monitor gene expression and perform SNP/genotype mapping. Our mission is to provide RNA expression and genomic DMA analysis in a consistent and timely manner that is of the highest quality for all of our Facility's users. In addition to providing experimental expertise for performing gene expression and SNP/genotype mapping protocols, the staff provides advice and consultation on experimental design, and data analysis approaches and statistics for microarray based research. Currently, the primary use of this technology is to determine the differential expression patterns of genes, either within cells or tissues. This technology enables investigators to compare patterns of expression in diseased and normal cells, cancer cells and non-cancerous cells and in different tissue types. The goal of these types of studies is to better understand the processes that potentially lead to diseased states and to find new or better ways of either controlling or stopping the progression of diseased states. A rapidly increasing use of this technology is analysis of genotypic variants (SNPs) to map disease-causing genes. These types of approaches will provide insight into multifactorial disease states. Genomewide information unlike individual gene information can be used to understand the more subtle patterns of diseases caused by multiple genes or by the confluence of environmental and genetic factors. Because of the great amount of detailed information provided from genomewide arrays, it is likely that microarrays will become an even more important tool not only in understanding disease processes, but also in disease diagnosis and the design of individualized therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA062203-18
Application #
8740836
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-09-11
Project End
2014-01-31
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
18
Fiscal Year
2013
Total Cost
$9,195
Indirect Cost
$3,577
Name
University of California Irvine
Department
Type
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92697
Chakraborty, Mahul; VanKuren, Nicholas W; Zhao, Roy et al. (2018) Hidden genetic variation shapes the structure of functional elements in Drosophila. Nat Genet 50:20-25
Morozko, Eva L; Ochaba, Joseph; Hernandez, Sarah J et al. (2018) Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice. J Huntingtons Dis 7:321-335
Carpenter, Philip M; Ziogas, Argyrios; Markham, Emma M et al. (2018) Laminin 332 expression and prognosis in breast cancer. Hum Pathol 82:289-296
Yan, Huaming; Romero-López, Mónica; Benitez, Lesly I et al. (2018) Multiscale modeling of glioblastoma. Transl Cancer Res 7:S96-S98
Yu, James; Landberg, Jenny; Shavarebi, Farbod et al. (2018) Bioengineering triacetic acid lactone production in Yarrowia lipolytica for pogostone synthesis. Biotechnol Bioeng 115:2383-2388
Oliver, Andrew; Kay, Matthew; Cooper, Kerry K (2018) Comparative genomics of cocci-shaped Sporosarcina strains with diverse spatial isolation. BMC Genomics 19:310
Mahlbacher, Grace; Curtis, Louis T; Lowengrub, John et al. (2018) Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment. J Immunother Cancer 6:10
Neek, Medea; Tucker, Jo Anne; Kim, Tae Il et al. (2018) Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses. Biomaterials 156:194-203
McLelland, Bryce T; Lin, Bin; Mathur, Anuradha et al. (2018) Transplanted hESC-Derived Retina Organoid Sheets Differentiate, Integrate, and Improve Visual Function in Retinal Degenerate Rats. Invest Ophthalmol Vis Sci 59:2586-2603
Bota, Daniela A; Chung, Jinah; Dandekar, Manisha et al. (2018) Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. CNS Oncol 7:CNS22

Showing the most recent 10 out of 1106 publications